Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04104516
Other study ID # UW19-597-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 26, 2019
Est. completion date April 30, 2021

Study information

Verified date April 2020
Source The University of Hong Kong
Contact LAI YK Agnes, PhD
Phone 852-9317-6328
Email agneslai@hku.hk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lung cancer is the leading cause of deaths in the world. Engagement in physical activity can provide important benefits for cancer patients. The current study is a cross-sectional questionnaire survey and in-depth interview to understand the physical activity preferences of patients with lung cancer. This process could help to develop a lifestyle modification program based on our patients' needs and preferences.


Description:

Lung cancer is one of the most common cancer globally and locally. Patients with lung cancer are in a uniquely difficult situation in their disease, comorbidities, and treatment that may lead to worsened symptoms and many negative health consequences, including fatigue, irritability, and impaired daytime functioning.

Physical activity (PA) is defined as 'any bodily movement produced by skeletal muscle that results in energy expenditure'. Several health benefits of increased PA have been reported for people with cancer. PA plays a critical role across the cancer trajectory, from prevention through to post-diagnosis and has been proposed as an alternative for improving physical and psychosocial health outcomes, reducing cancer recurrence, and cancer-specific and all-cause mortality. However, most of the findings were predominantly in breast and colorectal cancers. The PA dosage required to attain health benefits across these cancer groups is not uniform, nor is it clear whether the results can be applied to other groups of people with cancer.

The current study includes a cross-sectional questionnaire survey and an in-depth interview. It aims to understand the current physical activity practice and preference of patients with lung cancer, which could help to develop a lifestyle modification program based on our patients' needs and preferences.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Aged 18 years and above;

- Diagnosis with non-small cell lung cancer

- General condition stable, either is undergoing or finished treatment

- Able to speak and read Chinese

- Able to complete the self-administered questionnaire

- Mental, cognitive and physically fit for joining the trial as determined by the clinician or responsible investigator

Exclusion Criteria:

- Mentally unfit for answering questionnaire

- Unable to give informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

References & Publications (2)

Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985 Mar-Apr;100(2):126-31. — View Citation

Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvão DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019 Feb 11;2:CD012685. doi: 10.1002/14651858.CD012685.pub2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Preference on physical activity program Outcome-based questions with categorical choices immediately after obtaining written consent
Secondary Current physical activity practise Outcome-based questions with categorical choices immediately after obtaining written consent
Secondary Preference on information to be received Outcome-based questions with categorical choices immediately after obtaining written consent
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk